Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used medications. NSAIDs profoundly modify prostaglandin homeostasis through inhibition of the enzyme, cyclooxygenase (COX), especially COX-2. COX-2 inhibition is associated with adverse cardiovascular outcomes as demonstrated by recent trials using this type of drug. This review explores the latest available data, including recent, randomized, clinical trials, controversies, and pathophysiology of the adverse effects of COX-inhibition.
Copyright © 2015 Elsevier Inc. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Cardiovascular Diseases / enzymology
-
Cardiovascular Diseases / etiology*
-
Cardiovascular Diseases / physiopathology
-
Case-Control Studies
-
Cyclooxygenase 1 / drug effects
-
Cyclooxygenase 1 / metabolism*
-
Cyclooxygenase 2 / drug effects
-
Cyclooxygenase 2 / metabolism*
-
Female
-
Follow-Up Studies
-
Homeostasis / drug effects
-
Humans
-
Lactones / adverse effects
-
Lactones / therapeutic use
-
Male
-
Middle Aged
-
Naproxen / adverse effects
-
Naproxen / therapeutic use
-
Prevalence
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Sulfones / adverse effects
-
Sulfones / therapeutic use
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Lactones
-
Sulfones
-
rofecoxib
-
Naproxen
-
Cyclooxygenase 1
-
Cyclooxygenase 2